SCHEMBL1807910

SCHEMBL1807910

CC(=O)N(C[C@@H]1CN(Cc2ccc(Cl)c(Cl)c2)CCO1)Sc1nc(C(=O)NCCC(N)=O)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 2/20 0.44
DRD4 P21917 6/20 0.39
LMNA P02545 2/20 0.36
KCNH2 Q12809 2/20 0.36
SIGMAR1 Q99720 2/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
CYP2C9 P11712 1/20 0.36
ADRA2B P18089 1/20 0.36
HTR2C P28335 1/20 0.36
SLC6A4 P31645 1/20 0.36
CYP2C19 P33261 1/20 0.36
DRD3 P35462 1/20 0.36
HTR2B P41595 1/20 0.36
KMT2A Q03164 1/20 0.36
GRM2 Q14416 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1806588 0.94 CCR3 (0.41) CCR3DRD4LMNAKCNH2SIGMAR1
Hydrochloric Acid SCHEMBL1806817 0.93 CCR3 (0.41) CCR3DRD4LMNAKCNH2SIGMAR1
SCHEMBL1809736 0.93 CCR3 (0.45) CCR3DRD4LMNAKCNH2SIGMAR1
SCHEMBL1806144 0.90 CCR3 (0.39) CCR3DRD4LMNAKCNH2SIGMAR1
SCHEMBL1811133 0.89 CCR3 (0.47) CCR3DRD4KCNH2SIGMAR1GRM2
Hydrochloric Acid SCHEMBL1809318 0.89 CCR3 (0.42) CCR3DRD4LMNAKCNH2SIGMAR1
SCHEMBL1810235 0.87 DRD4 (0.44) CCR3DRD4KCNH2SIGMAR1CYP1A2
SCHEMBL1809367 0.86 CCR3 (0.40) CCR3DRD4LMNAKCNH2SIGMAR1
SCHEMBL1813440 0.86 CCR3 (0.42) CCR3DRD4LMNAKCNH2SIGMAR1
Hydrochloric Acid SCHEMBL1808736 0.86 CCR3 (0.40) CCR3DRD4LMNAKCNH2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 CCR3 1/4885DRD4 768/4885LMNA 2526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.